Leqembi’s sales curve just got a new number. BioArctic investors may not ignore it
Leqembi’s Alzheimer’s rollout is still slow, but Eisai’s 2028 sales simulation keeps BioArctic’s royalty story alive.
Lupin just cracked China with a flu drug. Why investors may want to look closer
Lupin’s China debut starts with flu medicine. The bigger story is whether one approval can open a larger paediatric pharma pathway.
LEO Pharma wins China approval for Enstilar, but can topical psoriasis leadership scale in the world’s biggest patient market?
LEO Pharma has won China approval for Enstilar in plaque psoriasis. Read what it means for competition, access, and dermatology growth.
Mazdutide shows weight loss efficacy in Chinese teens: Phase 1b results raise hopes for approval
Innovent Biologics has reported that mazdutide, its dual GLP-1 and glucagon receptor agonist, achieved statistically significant reductions in both body mass index and weight in Chinese adolescents with obesity during a 12-week Phase 1b clinical trial. The trial met its primary endpoint, demonstrated a favorable safety profile, and paves the way for a Phase 3 […]